MDACC Study No:2012-0721 ( NCT No: NCT01744652)
Title:A Phase I Trial of Dasatinib in Combination with Crizotinib
in Patients with Advanced Malignancies
Principal Investigator:David S. Hong
Treatment Agent:Crizotinib; Dasatinib
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination of dasatinib and crizotinib that can be given to patients
with advanced cancer. The safety of this drug combination will also be

Dasatinib is designed to block certain proteins from causing cancer cells to
grow out of control. This may cause the cancer cells to die.

Crizotinib is designed to block certain abnormal genes found in cancer cells.
This may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Crizotinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Pfizer
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:David S. Hong
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-763-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults